Randomized trials with Rd as frontline treatment for transplantation-ineligible patients with myeloma
| Induction (duration) . | First1 . | SWOG S0774 . | Endurance5 . | Tourmaline 21 . | Maia8 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rd continuous . | Rd 72 w (18 cycles) . | Rd 24 wk . | VRd 24 wk . | VRd 36 wk . | KRd 36 wk . | Rd 72 wk . | IRd 72 wk . | Rd continuous . | DRd 24 wk . | |
| No. of patients | 535 | 541 | 261 | 264 | 542 | 545 | 351 | 354 | 369 | 368 |
| Maintenance | Rd continuous | No | Rd continuous | Rd continuous | Len continuous or 2 y | Len continuous or 2 y | Len continuous | Ixa + Len continuous | Rd continuous | DRd 2 y then Dara continuous |
| Age, y | Med, 73 | Med, 73 | ≥65 y, 47% | ≥65 y, 39% | Med, 64 | Med, 65 | Med, 74 | Med, 73 | Med, 73 | Med, 74 |
| >75 y, 35% | >75 y, 36% | ≥70 y, 31% | ≥70 y, 32% | ≥75 y, 44% | ≥75 y, 43% | ≥75 y, 43.5% | ≥75 y, 43.6% | |||
| High-risk cytogenetics, % | 17 | 20 | NE | NE | 0 | 0 | 17.8 | 17.1 | 13.6 | 15 |
| Med PFS, mo | 26 | 21 | 29 | 41 | 34.4 | 34.6 | 21.8 | 35.3 | 34.4 | NR |
| 60% at 30 | ||||||||||
| ≥CR, % | 22 | 20 | 12.1 | 24.2 | 15 | 18 | 14.1 | 25.6 | 24.9 | 47.6 |
| ≥CR + VGPR, % | 48 | 47 | 53.2 | 74.9 | 65 | 75 | 47.7 | 63 | 53.1 | 79.3 |
| OS, mo | Med, 59.3 | Med, 62.3 | 5 y, 56% | 5 y, 69% | 3 y, 84% | 3 y, 86% | NR at 58 | NR at 58 | 3 y, 70% | 3 y, 80% |
| Induction (duration) . | First1 . | SWOG S0774 . | Endurance5 . | Tourmaline 21 . | Maia8 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rd continuous . | Rd 72 w (18 cycles) . | Rd 24 wk . | VRd 24 wk . | VRd 36 wk . | KRd 36 wk . | Rd 72 wk . | IRd 72 wk . | Rd continuous . | DRd 24 wk . | |
| No. of patients | 535 | 541 | 261 | 264 | 542 | 545 | 351 | 354 | 369 | 368 |
| Maintenance | Rd continuous | No | Rd continuous | Rd continuous | Len continuous or 2 y | Len continuous or 2 y | Len continuous | Ixa + Len continuous | Rd continuous | DRd 2 y then Dara continuous |
| Age, y | Med, 73 | Med, 73 | ≥65 y, 47% | ≥65 y, 39% | Med, 64 | Med, 65 | Med, 74 | Med, 73 | Med, 73 | Med, 74 |
| >75 y, 35% | >75 y, 36% | ≥70 y, 31% | ≥70 y, 32% | ≥75 y, 44% | ≥75 y, 43% | ≥75 y, 43.5% | ≥75 y, 43.6% | |||
| High-risk cytogenetics, % | 17 | 20 | NE | NE | 0 | 0 | 17.8 | 17.1 | 13.6 | 15 |
| Med PFS, mo | 26 | 21 | 29 | 41 | 34.4 | 34.6 | 21.8 | 35.3 | 34.4 | NR |
| 60% at 30 | ||||||||||
| ≥CR, % | 22 | 20 | 12.1 | 24.2 | 15 | 18 | 14.1 | 25.6 | 24.9 | 47.6 |
| ≥CR + VGPR, % | 48 | 47 | 53.2 | 74.9 | 65 | 75 | 47.7 | 63 | 53.1 | 79.3 |
| OS, mo | Med, 59.3 | Med, 62.3 | 5 y, 56% | 5 y, 69% | 3 y, 84% | 3 y, 86% | NR at 58 | NR at 58 | 3 y, 70% | 3 y, 80% |
CR, complete response; Dara, daratumumab; DRd, daratumumab plus Rd; Ixa, ixazomib; KRd, carfilzomib plus Rd; Len, lenalidomide; Med, median; NE, not evaluated; NR, not reached; VGPR, very good partial response; VRd, bortezomib plus Rd.